Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
VioQuest Pharmaceuticals (OTCBB: VOQP) today provided a strategic alternatives review and operations update. As disclosed in the Company?s periodic filings with the SEC...
VioQuest Pharmaceuticals (OTCBB: VOQP) today announced that the United States Patent and Trademark Office has issued the first patent for the company?s investigational product...
BOSTON, Aug. 25 /PRNewswire/ -- Scimitar Equity, LLC issues a review of VioQuest Pharmaceuticals, Inc (OTC:VOQP) (BULLETIN BOARD: VOQP) , entitled, "Creating Value; Turnaround Leverages Product...
VioQuest Pharmaceuticals, Inc. (OTCBB: VOQP) today reported its financial results for the three- and six-month periods ended June 30, 2008, and provided an update on recent...
VioQuest Pharmaceuticals (OTCBB: VOQP) announced today that the company?s novel Akt inhibitor VQD-002 (triciribine phosphate monohydrate, or TCN-P) has been selected as one of...
BOSTON, July 29 /PRNewswire/ -- Scimitar Equity, LLC issues a review of VioQuest Pharmaceuticals, Inc (OTC:VOQP) (BULLETIN BOARD: VOQP) , entitled, "510k Application Submitted for Xyfid(TM) and...
VioQuest Pharmaceuticals (OTCBB: VOQP) announced that Christopher P. Schnittker, CPA, has joined the company as vice president and chief financial officer (CFO) effective today...
VioQuest Pharmaceuticals (OTCBB: VOQP) today announced the submission of a 510(k) application to the United States Food and Drug Administration (FDA). The application seeks...
VioQuest Pharmaceuticals (OTCBB: VOQP) today reported updated data from a Phase 1 dose escalation study evaluating Lenocta? (sodium stibogluconate) in combination with...
VioQuest Pharmaceuticals (OTCBB: VOQP) today reported its financial results for the first quarter ended March 31, 2008. For the first quarter of 2008, operating expenses...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 0 | 0 | CS |
| 26 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 0 | 0 | CS |
| 52 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 0 | 0 | CS |
| 156 | -0.002999 | -99.9666666667 | 0.003 | 0.003 | 1.0E-6 | 8 | 1.0E-6 | CS |
| 260 | -0.005999 | -99.9833333333 | 0.006 | 0.02 | 1.0E-6 | 12700 | 0.00647064 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
